Skip to main content
Erschienen in:

20.10.2023

Intracerebral hemorrhage mortality in individuals with atrial fibrillation: a nationwide analysis of mortality trends in the United States

verfasst von: Hoang Nhat Pham, Enkhtsogt Sainbayar, Ramzi Ibrahim, Justin Z. Lee

Erschienen in: Journal of Interventional Cardiac Electrophysiology | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Atrial fibrillation (AF) is a risk factor for intracerebral hemorrhage (ICH), both with and without use of anticoagulation. Limited data exists on mortality trends and disparities related to this phenomenon. We aimed to assess ICH mortality trends and disparities based on demographic factors in individuals with atrial fibrillation in the United States (US).

Methods

Our cross-sectional analysis utilized mortality data from the CDC database through death certificate queries from the years 1999 to 2020 in the US. We queried for all deaths with ICH as the underlying cause of death and atrial fibrillation as the multiple causes of death. Mortality data was obtained for overall population and demographic subpopulations based on sex, race and ethnicity, and geographic region. Trend analysis and average annual-mortality percentage change (AAPC) were completed using log-linear regression models.

Results

ICH age-adjusted mortality rate (AAMR) in patients with AF increased from 0.27 (95% CI 0.25–0.29) in 1999 to 0.30 (95% CI 0.29–0.32) in 2020. A higher mortality rate was observed in males (AAMR 0.33) than in females (AAMR 0.26). The highest mortality was found in Asian/Pacific Islander (AAMR: 0.32) populations, followed by White (AAMR: 0.30), Black (AAMR: 0.15), and American Indian/Alaska Native (AAMR: 0.11) populations. Southern (AAPC: 1.3%) and non-metropolitan US regions (AAPC: + 1.9%) had the highest increase in annual mortality change.

Conclusion

Our findings highlight the disparities in ICH mortality in patients with AF. Further investigation is warranted to confirm these findings and evaluate for contributors to the observed disparities.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217–21.CrossRefPubMed Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217–21.CrossRefPubMed
3.
Zurück zum Zitat Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.CrossRefPubMed Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.CrossRefPubMed
4.
5.
Zurück zum Zitat Franco L, et al. Mortality in patients with intracerebral hemorrhage associated with antiplatelet agents, oral anticoagulants or no antithrombotic therapy. Eur J Intern Med. 2020;75:35–43.CrossRefPubMed Franco L, et al. Mortality in patients with intracerebral hemorrhage associated with antiplatelet agents, oral anticoagulants or no antithrombotic therapy. Eur J Intern Med. 2020;75:35–43.CrossRefPubMed
6.
Zurück zum Zitat Lopes RD, et al. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. Blood. 2017;129(22):2980–7.CrossRefPubMed Lopes RD, et al. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. Blood. 2017;129(22):2980–7.CrossRefPubMed
7.
Zurück zum Zitat Franke CL, et al. Intracerebral hematomas during anticoagulant treatment. Stroke. 1990;21(5):726–30.CrossRefPubMed Franke CL, et al. Intracerebral hematomas during anticoagulant treatment. Stroke. 1990;21(5):726–30.CrossRefPubMed
8.
Zurück zum Zitat Piran S, Schulman S. Treatment of bleeding complications in patients on anticoagulant therapy. Blood. 2019;133(5):425–35.CrossRefPubMed Piran S, Schulman S. Treatment of bleeding complications in patients on anticoagulant therapy. Blood. 2019;133(5):425–35.CrossRefPubMed
9.
Zurück zum Zitat Seelig J, et al. When to withhold oral anticoagulation in atrial fibrillation - an overview of frequent clinical discussion topics. Vasc Health Risk Manag. 2019;15:399–408.CrossRefPubMedPubMedCentral Seelig J, et al. When to withhold oral anticoagulation in atrial fibrillation - an overview of frequent clinical discussion topics. Vasc Health Risk Manag. 2019;15:399–408.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Granger CB, Pokorney SD. Preventing and Managing Bleeding With Anticoagulation for Atrial Fibrillation. J Am Coll Cardiol. 2021;77(24):3002–4.CrossRefPubMed Granger CB, Pokorney SD. Preventing and Managing Bleeding With Anticoagulation for Atrial Fibrillation. J Am Coll Cardiol. 2021;77(24):3002–4.CrossRefPubMed
11.
Zurück zum Zitat Center for Disease Control and Prevention National Center for Health Statistics. CDC wonder: multiple cause of death 1999–2020. Center for Disease Control and Prevention. https://wonder.cdc.gov/mcd.html. Accessed 1 June 2023. Center for Disease Control and Prevention National Center for Health Statistics. CDC wonder: multiple cause of death 1999–2020. Center for Disease Control and Prevention. https://​wonder.​cdc.​gov/​mcd.​html. Accessed 1 June 2023.
12.
Zurück zum Zitat Kim HJ, F.M., Feuer EJ, Midthune DN. "Permutation tests for joinpoint regression with applications to cancer rates". Stat Med. 2000; 19:335–351: (correction: 2001;20:655). Kim HJ, F.M., Feuer EJ, Midthune DN. "Permutation tests for joinpoint regression with applications to cancer rates". Stat Med. 2000; 19:335–351: (correction: 2001;20:655).
15.
Zurück zum Zitat Kim HJ, Yu B, Feuer EJ. Selecting the Number of Change-Points in Segmented Line Regression. Stat Sin. 2009;19(2):597–609.PubMedPubMedCentral Kim HJ, Yu B, Feuer EJ. Selecting the Number of Change-Points in Segmented Line Regression. Stat Sin. 2009;19(2):597–609.PubMedPubMedCentral
17.
Zurück zum Zitat Yu B, Barrett M, Kim H-J, Feuer EJ. Estimating Joinpoints in Continuous Time Scale for Multiple Change-Point Models. Comput Stat Data Anal. 2007;51:2420–7.CrossRef Yu B, Barrett M, Kim H-J, Feuer EJ. Estimating Joinpoints in Continuous Time Scale for Multiple Change-Point Models. Comput Stat Data Anal. 2007;51:2420–7.CrossRef
18.
Zurück zum Zitat Gabet A, Olie V, Bejot Y. Atrial Fibrillation in Spontaneous Intracerebral Hemorrhage, Dijon Stroke Registry (2006–2017). J Am Heart Assoc. 2021;10(17):e020040.CrossRefPubMedPubMedCentral Gabet A, Olie V, Bejot Y. Atrial Fibrillation in Spontaneous Intracerebral Hemorrhage, Dijon Stroke Registry (2006–2017). J Am Heart Assoc. 2021;10(17):e020040.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Hankey GJ, et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke. 2014;45(5):1304–12.CrossRefPubMed Hankey GJ, et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke. 2014;45(5):1304–12.CrossRefPubMed
20.
Zurück zum Zitat Hart RG, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012;43(6):1511–7.CrossRefPubMed Hart RG, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012;43(6):1511–7.CrossRefPubMed
21.
Zurück zum Zitat Steiner T, Weitz JI, Veltkamp R. Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents. Stroke. 2017;48(5):1432–7.CrossRefPubMed Steiner T, Weitz JI, Veltkamp R. Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents. Stroke. 2017;48(5):1432–7.CrossRefPubMed
22.
Zurück zum Zitat Flibotte JJ, et al. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63(6):1059–64.CrossRefPubMed Flibotte JJ, et al. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63(6):1059–64.CrossRefPubMed
23.
Zurück zum Zitat Ayala C, et al. Sex differences in US mortality rates for stroke and stroke subtypes by race/ethnicity and age, 1995–1998. Stroke. 2002;33(5):1197–201.CrossRefPubMed Ayala C, et al. Sex differences in US mortality rates for stroke and stroke subtypes by race/ethnicity and age, 1995–1998. Stroke. 2002;33(5):1197–201.CrossRefPubMed
24.
Zurück zum Zitat Morgenstern LB, Spears WD. A triethnic comparison of intracerebral hemorrhage mortality in Texas. Ann Neurol. 1997;42(6):919–23.CrossRefPubMed Morgenstern LB, Spears WD. A triethnic comparison of intracerebral hemorrhage mortality in Texas. Ann Neurol. 1997;42(6):919–23.CrossRefPubMed
26.
Zurück zum Zitat Daly DJ, et al. Race, ethnicity, sex, and socioeconomic disparities in anticoagulation for atrial fibrillation: A narrative review of contemporary literature. J Natl Med Assoc. 2023;115(3):290–7.PubMed Daly DJ, et al. Race, ethnicity, sex, and socioeconomic disparities in anticoagulation for atrial fibrillation: A narrative review of contemporary literature. J Natl Med Assoc. 2023;115(3):290–7.PubMed
27.
Zurück zum Zitat Shen AY, et al. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50(4):309–15.CrossRefPubMed Shen AY, et al. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50(4):309–15.CrossRefPubMed
28.
Zurück zum Zitat Ayala C, et al. Racial/ethnic disparities in mortality by stroke subtype in the United States, 1995–1998. Am J Epidemiol. 2001;154(11):1057–63.CrossRefPubMed Ayala C, et al. Racial/ethnic disparities in mortality by stroke subtype in the United States, 1995–1998. Am J Epidemiol. 2001;154(11):1057–63.CrossRefPubMed
29.
Zurück zum Zitat Klatsky AL, et al. Risk of hemorrhagic stroke in Asian American ethnic groups. Neuroepidemiology. 2005;25(1):26–31.CrossRefPubMed Klatsky AL, et al. Risk of hemorrhagic stroke in Asian American ethnic groups. Neuroepidemiology. 2005;25(1):26–31.CrossRefPubMed
30.
Zurück zum Zitat Tedla YG, et al. Racial Disparity in the Prescription of Anticoagulants and Risk of Stroke and Bleeding in Atrial Fibrillation Patients. J Stroke Cerebrovasc Dis. 2020;29(5):104718.CrossRefPubMed Tedla YG, et al. Racial Disparity in the Prescription of Anticoagulants and Risk of Stroke and Bleeding in Atrial Fibrillation Patients. J Stroke Cerebrovasc Dis. 2020;29(5):104718.CrossRefPubMed
31.
Zurück zum Zitat Bassand JP, et al. Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. Blood Adv. 2021;5(4):1081–91.CrossRefPubMedPubMedCentral Bassand JP, et al. Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. Blood Adv. 2021;5(4):1081–91.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Daniel D, et al. Variability in Intensive Care Utilization for Intracerebral Hemorrhage in the United States: Retrospective Cohort Study. J Stroke Cerebrovasc Dis. 2022;31(8):106619.CrossRefPubMed Daniel D, et al. Variability in Intensive Care Utilization for Intracerebral Hemorrhage in the United States: Retrospective Cohort Study. J Stroke Cerebrovasc Dis. 2022;31(8):106619.CrossRefPubMed
33.
Zurück zum Zitat Bako AT, et al. Geographic Disparities in Case Fatality and Discharge Disposition Among Patients With Primary Intracerebral Hemorrhage. J Am Heart Assoc. 2023;12(10):e027403.CrossRefPubMedPubMedCentral Bako AT, et al. Geographic Disparities in Case Fatality and Discharge Disposition Among Patients With Primary Intracerebral Hemorrhage. J Am Heart Assoc. 2023;12(10):e027403.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Harrington RA, et al. Call to Action: Rural Health: A Presidential Advisory From the American Heart Association and American Stroke Association. Circulation. 2020;141(10):e615–44.CrossRefPubMed Harrington RA, et al. Call to Action: Rural Health: A Presidential Advisory From the American Heart Association and American Stroke Association. Circulation. 2020;141(10):e615–44.CrossRefPubMed
36.
Zurück zum Zitat Leira R, et al. Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors. Neurology. 2004;63(3):461–7.CrossRefPubMed Leira R, et al. Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors. Neurology. 2004;63(3):461–7.CrossRefPubMed
40.
Zurück zum Zitat Feigin VL, et al. Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990–2013: The GBD 2013 Study. Neuroepidemiology. 2015;45(3):161–76.CrossRefPubMed Feigin VL, et al. Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990–2013: The GBD 2013 Study. Neuroepidemiology. 2015;45(3):161–76.CrossRefPubMed
41.
Zurück zum Zitat Bejot Y, et al. Intracerebral haemorrhage profiles are changing: results from the Dijon population-based study. Brain. 2013;136(Pt 2):658–64.CrossRefPubMed Bejot Y, et al. Intracerebral haemorrhage profiles are changing: results from the Dijon population-based study. Brain. 2013;136(Pt 2):658–64.CrossRefPubMed
42.
Zurück zum Zitat Chugh SS, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–47.CrossRefPubMed Chugh SS, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–47.CrossRefPubMed
43.
Zurück zum Zitat Lovelock CE, et al. Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study. Lancet Neurol. 2007;6(6):487–93.CrossRefPubMed Lovelock CE, et al. Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study. Lancet Neurol. 2007;6(6):487–93.CrossRefPubMed
44.
Zurück zum Zitat Tseng ZH, et al. Prospective Countywide Surveillance and Autopsy Characterization of Sudden Cardiac Death: POST SCD Study. Circulation. 2018;137(25):2689–700.CrossRefPubMedPubMedCentral Tseng ZH, et al. Prospective Countywide Surveillance and Autopsy Characterization of Sudden Cardiac Death: POST SCD Study. Circulation. 2018;137(25):2689–700.CrossRefPubMedPubMedCentral
Metadaten
Titel
Intracerebral hemorrhage mortality in individuals with atrial fibrillation: a nationwide analysis of mortality trends in the United States
verfasst von
Hoang Nhat Pham
Enkhtsogt Sainbayar
Ramzi Ibrahim
Justin Z. Lee
Publikationsdatum
20.10.2023
Verlag
Springer US
Erschienen in
Journal of Interventional Cardiac Electrophysiology / Ausgabe 5/2024
Print ISSN: 1383-875X
Elektronische ISSN: 1572-8595
DOI
https://doi.org/10.1007/s10840-023-01674-x

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Kardiologie

Vorhofflimmern: Antikoagulation vor Schlaganfall von Vorteil

Erleiden Menschen mit Vorhofflimmern einen ischämischen Schlaganfall, ist dieser weniger schwer, auch sind Infarktgröße und Blutungsrisiko geringer, wenn sie zuvor orale Antikoagulanzien erhalten haben. Die Art der Antikoagulation spielt dabei keine Rolle.

Mehr Cholesterin im Essen = höheres Herzinfarktrisiko

Je mehr Cholesterin man täglich über die Nahrung zu sich nimmt, desto höher ist offenbar das Herzinfarktrisiko – das legt eine Studie mit US-Veteranen zumindest für Männer nahe.

Antikoagulation bei Vorhofflimmern: Sind DOAK noch zu toppen?

Gegen Thromboembolien so wirksam wie ein DOAK, bei zugleich geringerem Blutungsrisiko – werden Faktor-XI-Hemmer als neue Antikoagulanzien dieser Erwartung gerecht? Eine aktuell publizierte Vergleichsstudie gibt darüber Aufschluss.

"Stammzell-Pflaster" gegen geschwächte Herzen: Hoffnung oder Hype?

Eine Nature-Publikation zur Behandlung der Herzinsuffizienz mit von Stammzellen abgeleiteten Herzzellen sorgt in Publikumsmedien für Wirbel. Deren Erkenntnisse sind in der Tat spektakulär – und gleichzeitig vorläufig und ernüchternd. 

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.